PHARMA INDUSTRY SOLUTIONS: The 80/20 Non-Profit Pharma Company

Lets all face it. #Healthcare and #Pharma in particular are crying out for change. Many have suggested ways to catalyze this change, but few to none have actually brought it. Through us: Solved.
It is common knowledge: the pharmaceutical industry, to continually innovative, needs to more easily and collaboratively develop medicines.
A Group of pharmaceutical scientists and pharmaceutical companies asked us: "With your new type of encryption, with your Pharmaceutical Token (Ticker: PHARMA), and with your eNFT Marketplace for Medicines....where will you place these eNFT Investments using your organizations DeFi methods for a new type of financing for medicine, to both make a profit and solve the healthcare problem at the same time." My Answer?: We are going to focus exclusively on developing #WonderDrugs, using a Non-Profit 80/20 Model that is unique and super-focused on both ROI and the "big picture" of using not-for-profit and #Research means to help humankind. The 20 in this model represents #ForProfit built-in. This way, #GlobalHumanHealth gets the #MaxBenefit
REQUIRED READING: Nonprofit Pharmaceutical Companies: Background, Challenges, and Policy Options - By Waxman Strategies.
Blockchain BioPharma is a Desktop Software Application for #Governments, #Universities, and #PHAMA Companies to collaborative on eNFT's for Medicine. Our software is built with an Enterprise Multi-Factor Encryption called Quantum SSO.
The Blockchain BioPharma Answer?: We are going to focus exclusively on developing #WonderDrugs using a Non-Profit 80/20 Model allows a unique and super-focused model on both ROI and the "big picture" of using Not-for-profit and R&D means to help humankind. The 20 in this model represents #ForProfit built-in. This way, #GlobalHumanHealth gets the #MaxBenefit, while #Tokenomics and #Economics are still focused on generating revenue.
REQUIRED READING: Nonprofit Pharmaceutical Companies: Background, Challenges, and Policy Options - By Waxman Strategies.